# Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

> **NCT04563702** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 35 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** VXA-CoV2-1

## Key facts

- **NCT ID:** NCT04563702
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2021-10-10
- **Final completion:** 2021-10-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563702, "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04563702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*